Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study by Tyren M Dodgen et al.
Dodgen et al. BMC Medical Genetics 2013, 14:20
http://www.biomedcentral.com/1471-2350/14/20RESEARCH ARTICLE Open AccessIntroduction of the AmpliChip CYP450 Test to a
South African cohort: a platform comparative
prospective cohort study
Tyren M Dodgen1, Warren E Hochfeld1, Heidi Fickl2, Sahle M Asfaha2, Chrisna Durandt2, Paul Rheeder3,
Britt I Drögemöller4, Galen E B Wright4, Louise Warnich4, Christiaan DJ Labuschagne5, Antoinette van Schalkwyk5,
Andrea Gaedigk6 and Michael S Pepper2,7*Abstract
Background: Adverse drug reactions and lack of therapeutic efficacy associated with currently prescribed
pharmacotherapeutics may be attributed, in part, to inter-individual variability in drug metabolism. Studies on the
pharmacogenetics of Cytochrome P450 (CYP) enzymes offer insight into this variability. The objective of this study
was to compare the AmpliChip CYP450 TestW (AmpliChip) to alternative genotyping platforms for phenotype
prediction of CYP2C19 and CYP2D6 in a representative cohort of the South African population.
Methods: AmpliChip was used to screen for thirty-three CYP2D6 and three CYP2C19 alleles in two different cohorts.
As a comparison cohort 2 was then genotyped using a CYP2D6 specific long range PCR with sequencing (CYP2D6
XL-PCR + Sequencing) platform and a PCR-RFLP platform for seven CYP2C19 alleles.
Results: Even though there was a low success rate for the AmpliChip, allele frequencies for both CYP2D6 and
CYP2C19 were very similar between the two different cohorts. The CYP2D6 XL-PCR + Sequencing platform detected
CYP2D6*5 more reliably and could correctly distinguish between CYP2D6*2 and *41 in the Black African individuals.
Alleles not covered by the AmpliChip were identified and four novel CYP2D6 alleles were also detected. CYP2C19
PCR-RFLP identified CYP2C19*9,*15, *17 and *27 in the Black African individuals, with *2, *17 and *27 being relatively
frequent in the cohort. Eliminating mismatches and identifying additional alleles will contribute to improving
phenotype prediction for both enzymes. Phenotype prediction differed between platforms for both genes.
Conclusion: Comprehensive genotyping of CYP2D6 and CYP2C19 with the platforms used in this study, would be
more appropriate than AmpliChip for phenotypic prediction in the South African population. Pharmacogenetically
important novel alleles may remain undiscovered when using assays that are designed according to Caucasian
specific variation, unless alternate strategies are utilised.Background
Inter-individual pharmacokinetic variability may account
for the significant range in drug responses observed in
the clinical setting. Response can be experienced both in
terms of pronounced adverse drug reactions (ADRs) and
inability to reach therapeutic levels. Cytochrome P450
(CYP) enzymes are estimated to be responsible for up to
86% of Phase I metabolism of commonly prescribed* Correspondence: michael.pepper@up.ac.za
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reproduction in any medium, provided the ortherapeutic drugs [1]. Of the CYP enzymes, CYP2D6
and CYP2C19 have been estimated to metabolise ap-
proximately 25% [2] and 8% [3] of these commonly pre-
scribed drugs, respectively. CYP2D6 is involved in the
metabolism of antidepressants, selective serotonin re-
uptake inhibitors, antipsychotics antiarrhythmics, β-
blockers and opioid analgesics; while CYP2C19 is
involved in the metabolism of proton pump inhibitors,
benzodiazepines, tricyclic antidepressants, selective sero-
tonin reuptake inhibitors, barbiturates, anti-malarial
agents, anticonvulsants, monoamine oxidise inhibitors
and platelet aggregation inhibitors [4-6].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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genetic mutations present in drug metabolising enzymes
have been the predominant focus of pharmacogenetic
studies. Due to the complexity and vast number of
mutations present in these genes, the Human Cyto-
chrome P450 (CYP) Allele Nomenclature website was
created in order to catalogue genetic variability in CYP
enzymes (www.cypalleles.ki.se/). Over 100 alleles for
CYP2D6 and 28 alleles for CYP2C19 have been
described to date (27 November 2012). For a subset of
the alleles, in vivo and/or in vitro studies have elucidated
enzyme activities and these activities are listed as
increased, normal, decreased or none. This information
can be used, along with genotype, to predict the poor
(PM), intermediate (IM), extensive (EM) or ultra-rapid
metaboliser (UM) status of the CYP genes [6]. Clinicians
could potentially use this predicted metaboliser status to
personalise prescription, with the intention of reducing
ADRs and increasing therapeutic efficacy. Pharmacogen-
etics has been estimated to potentially reduce ADRs by
10-20% and to improve efficacy by 10-15%, and under-
lies the rationale for pharmacogenetic screening [5].
In order for a pharmacogenetic screening assay to be
effective, it must be able to deal with highly polymorphic
genes with high throughput capability in an efficient and
cost effective way. The Roche AmpliChip CYP450 TestW
(AmpliChip) was created with this in mind. In 2005, this
Affymetrix platform (Roche Molecular Systems, Inc.,
Branchburg, NJ) became the first DNA based microarray
to be approved by the Food and Drug Administration
(FDA) for CYP2C19 and CYP2D6 pharmacogenetics [7].
The AmpliChip is a high-throughput, comprehensive
screening assay designed to simultaneously identify
thirty-three CYP2D6 and three CYP2C19 alleles from
whole blood-derived DNA (http://www.amplichip.us/
documents/CYP450_P.I._US-IVD.pdf ). In an initial as-
sessment of the AmpliChip, de Leon et al. [8] said that,
“this new technology is a major step in ushering ‘perso-
nalized prescription’ into the clinical environment.”
Rebsamen et al. [9] observed that the AmpliChip is good
at predicting PMs and EMs, satisfactory in predicting
IMs, but not as efficient at predicting UMs. In summar-
ising, Rebsamen et al. [9] stated that, “this microarray
technology could be an excellent tool to improve pheno-
type prediction.” The AmpliChip has been validated for
CYP2D6 on German Caucasians (n=158, [10]), female
Swiss Caucasians (n=165, [9]) and a combined Cauca-
sian (n=3779) and African American (n = 452) cohort
[7]. Heller et al. [10] concluded that the AmpliChip was
fast, accurate and comprehensive in its identification of
CYP2D6 genotype and predicted phenotype. A summary
of these articles can be found in Table 1 where notably it
appears that there are more PMs in Caucasians than in
Black Africans and Koreans [7,9-13]. The only group toreport results for CYP2C19 was de Leon et al. [7]. This
study found that 98.0% of American Caucasians were
EM and 2.0% were PM (cohort: n=3938), with and allele
frequency of 14.2% for CYP2C19*2 and 0.0% for *3.
In comparison 96.0% of African Americans (cohort
size=478) were predicted to be EM and 4% were pre-
dicted to be PM, with allele frequencies of 18.3% for
CYP2C19*2 and 0.1% for *3 [7].
Although several populations of European descent
have been investigated using the AmpliChip, this assay
has not been used to genotype an African population
residing in Africa. Considering that novel alleles have
been found in African cohorts [14-18], it is important to
evaluate these genetically diverse populations when con-
sidering pharmacogenetic implementation. This needs to
be addressed, given that ADRs occur in an estimated
14% of hospitalised South African patients resulting in a
5–10 fold higher fatality compared to USA and UK hos-
pitals [19]. The implementation of a pharmacogenetic
assay may assist in reducing the socio-economic burden
associated with this sub-optimal treatment in South
Africa. The objective of this study was therefore to
evaluate the AmpliChip for use as a pharmacogenetic
screening tool for CYP2D6 and CYP2C19 in the South
African population.
Methods
Study subjects and sampling
Ethical approval was obtained from the Research Ethics
Committee, Faculty of Health Science, University of Pre-
toria (Approval numbers: Cohort 1 - 102/2005 and Co-
hort 2 - S132/2009) and the study was conducted in
accordance with the Declaration of Helsinki, using GCP
guidelines. All participating volunteers were ≥18 years of
age, South African citizens and resided in the city of
Pretoria during the sampling period. These cohorts
were chosen to be demographically representative of the
general population of South Africa (http://www.statssa.
gov.za/). It should be noted however, that it is not the
authors’ intention to use this study for inter-ethnic com-
parisons. Informed consent was obtained from all parti-
cipants along with general demographic information
including place of birth and voluntary disclosure of
ethnic group (Black African, Caucasian, Coloured and
Indian). The term Coloured, also referred to as Mixed
Ancestry in the South African context, is used officially
to describe an admixed group of people predominantly
residing in the Western Cape [20,21]. The admixture
present in this population is derived from several diffe-
rent ancestries including European, Asian and African,
primarily Khoisan and Bantu influence. The high level of
admixture can be attributed to the presence of the major
trade routes in South Africa during the fifteenth to nine-
teenth centuries [20,21].
Table 1 Summary of reported CYP2D6 genotyping studies using the AmpliChip CYP450 test





















Variant Allele frequency (%)
*1 38.2 40.7 46.9 36.2 35.5 37.4 59.7 35.7
*2 9.1 9.2 19.8 10.5 15.5 15.9 6.0 16.5
*3 0.0 0.0 0.0 3.0 0.6 1.8 0.2 0.5
*4 0.0 0.0 0.0 12.2 20.6 21.0 5.5 14.8
*5 3.6* 1.6* − 8.2 2.4 2.3 2.8 4.9
*6 0.0 0.0 0.0 2.6 1.2 1.1 0.2 0.5
*7 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0
*8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
*9 0.0 0.0 0.0 0.7 2.7 2.9 0.4 7.1
*10 47.3 46.1 33.3 1.6 2.7 1.0 3.8 4.4
*11 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
*14 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0
*15 − − − 0.0 0.0 0.0 0.0 0.0
*17 − − − 0.0 0.3 0.3 18.4 0.0
*18 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
*19 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
*20 − − − 0.0 0.0 0.0 0.0 0.5
*25 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
*26 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
*29 − − − 0.0 0.3 0.2 7.7 0.0
*30 − − − 0.0 0.0 0.0 0.0 0.0
*31 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
*35 − − − 6.6 7.3 4.8 0.9 4.4
*36 0.0* 0.0* − 0.0 0.0 0.0 0.6 0.0
*40 − − − 0.0 0.0 0.0 0.3 0.0
*41 1.4 2.2 0.0 6.3 7.3 9.8 14.9 9.3
*1xn − − − 6.6 0.6 0.7 0.8 0.5
*2xn − − − 4.9 1.5 0.5 1.2 0.5
*4xn − − − 0.3 0.3 0.1 2.4 0.0
*6xn − − − 0.0 0.0 0.0 0.0 0.0
*10xN − − − 0.0 0.0 0.0 0.0 0.0
*17xN − − − 0.0 0.0 0.0 0.2 0.0
*29xN − − − 0.0 0.0 0.0 0.2 0.0
*35xN − − − 0.3 0.0 0.0 0.0 0.0
*41xN − − − 0.0 0.9 0.1 0.0 0.0
Total
alleles
220 184 162 304 330 7558 904 182
Predicted phenotype
PM 0 (0.0) 0 (0.0)
Not reported
10.5 (16) 9.1 (15) 8.2 (311) 1.8 (8) 6.6 (6)
IM 23.6 (26) 25 (23.0) 4.0 (6) 7.9 (13) 9.7 (365) 32.7 (148) 11.0 (10)
EM 76.4 (84) 75 (69.0) 71.7 (109) 81.8 (135) 80.7 (3048) 63.5 (287) 81.3 (74)
UM − − 13.8 (21) 1.2 (2) 1.5 (55) 2.0 (9) 1.1 (1)
Cohort 110 92 81 152 165 3779 452 91
Alleles not covered by AmpliChip at the time of reporting are represented by “—”. The microarray used in the Nikoloff et al. (2002) paper did not cover CYP2D6*5;
however, a separate assay was used for *5 detection and the frequency was reported. Predicted phenotype reported or adjusted to represent AmpliChip test calls.
TD+; patients with tardive dyskinesia, TD- patients without tardive dyskinesia.
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Diabetic individuals (n=83): 57 Black African; 6 Cauca-
sian; 10 Coloured and 10 Indian. These individuals were
attending the Diabetic Clinic at the Steve Biko Academic
Hospital in Pretoria. This cohort was genotyped using
AmpliChip.
Cohort 2
Apparently healthy volunteers (n=100) were recruited
from several different sites in Pretoria. This cohort con-
sisted of 70 Black African, 10 Caucasian, 10 Coloured
and 10 Indian individuals. This cohort was used to
comparatively evaluate the AmpliChip platform using
PCR-RFLP and XL-PCR+Sequencing for CYP2C19 and
CYP2D6 respectively.
Genomic DNA (gDNA) extraction
Venous blood samples collected in ethylenediami-
netetraacetic acid (EDTA) vacutainer tubes (Becton-
Dickinson, Franklin Lakes, NJ, USA) were used for
gDNA extraction. Extraction was performed using the
Genomic DNA Purification Kit (Fermentas Life Science,
Lithuania) or the automated MaxwellW 16 system (Pro-
mega, Madison, WI, USA), and extraction was per-
formed according to the manufacturer’s instructions.
AmpliChip CYP450 Test
Each sample was simultaneously evaluated for
CYP2D6 and CYP2C19 using the AmpliChip CYP450
Test (Roche Molecular Systems Inc., Pleasanton,
CA, USA) according to the manufacturer’s protocol
(AmpliChip CYP450 Test package insert). In brief,
CYP2D6 and CYP2C19 were amplified in two separ-
ate reactions. Both reactions were monitored for
amplification using 1.0% agarose gel electrophoresis
for 1 hour (not in protocol). Reactions were pooled
and subjected to DNase I (Roche Molecular Systems
Inc.) fragmentation, following which the fragments
were 3’-end labelled using Terminal Transferase
(Roche Molecular Systems Inc.) and TdT Labelling
Reagent (supplied in the AmpliChip kit).
Using a pre-programmed protocol, the labelled frag-
ments were hybridised onto AmpliChip CYP450
microarrays, stained with streptavidin-conjugated phyco-
erythrin (Invitrogen Corp., Carlsbad, CA, USA) and
washed in an Affymetrix GeneChip Fluidics Station
450Dx (Affymetrix, Santa Clara, CA, USA). Each Ampli-
Chip was then scanned with an Affymetrix GeneChip
Scanner 3000Dx (Affymetrix). The resulting image
was orientated using GeneChip Operating Software
(Affymetrix) and transferred to AmpliChip CYP450 Data
Analysis Software (Roche Molecular Systems Inc.) to
determine CYP2D6 and CYP2C19 genotypes and pre-
dicted phenotypes.CYP2C19 Genotyping
The same gDNA samples analysed by AmpliChip were
also analysed by a PCR-RFLP platform designed for
South African Xhosa individuals [18]. This assay was
used to evaluate the ability of AmpliChip to genotype
the CYP2C19 variation present in the South African
population. Alleles identified and assayed were named
according the CYP Allele Nomenclature Committee’s
online database (http://www.cypalleles.ki.se/). This plat-
form focuses on identifying allele defining SNPs for
CYP2C19*2, *3, *9, *15, *17, *27 and *28 alleles (method
summarised in Additional file 1: Table S1 and Additional
file 2: Table S2).
CYP2D6 Long range PCR with sequencing
A CYP2D6 Long Range PCR with Sequencing (XL-PCR
+Sequencing) strategy was designed to genotype Cohort
2 and to assess the ability of AmpliChip to successfully
genotype the functionally significant alleles present in
the South African population. This alternate approach
included a series of long range PCR (XL-PCR) amplifica-
tions which were used for detection of CYP2D6*5
(complete gene deletion), CYP2D6 duplication (increased
copy number) and to amplify a CYP2D6 product for
sequencing (introns and exons). All primers (Additional
file 3: Table S3 and Additional file 4: Table S4) utili-
sed for amplification were manufactured by Inqaba
Biotechnical Industries (Pretoria, South Africa). The
amplification reactions (in detail below) were performed
using a Gold-plated 96-Well GeneAmp 9700 thermal
cycler (Applied Biosystems, Foster City, CA, USA),
followed by electrophoresis using 1.0% agarose gels
for 1 hour.
XL-PCR reactions detection of CYP2D6*5 and duplications
CYP2D6*5 detection was based on a duplex XL-PCR
assay described by Hersberger et al. [22]. This reac-
tion was performed using Long-Range Taq polymerase
(Fermentas Life Science). PCR reaction conditions were
optimised for primer concentration and denaturing time
to ensure equal amplification of the CYP2D6*5 deletion
fragment (3.2 kb) and the whole CYP2D6 gene fragment
(5.1 kb). Heterozygous samples were repeated using only
the CYP2D6 specific primers in order to generate the
5.1 kb amplicon for sequencing.
The XL-PCR duplex amplification reaction described
by Gaedigk et al. [23] was used to detect the presence
of CYP2D6 duplications (primers and conditions in
Additional file 3: Table S3). A separate XL-PCR reaction
amplified a duplication-specific product allowing ampli-
fication and characterisation of allelic status of the dupli-
cated gene [23]. The duplication-specific product was
characterised by re-sequencing (primers and conditions
in Additional file 3: Table S3).
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Prior to re-sequencing, amplified PCR products were
purified using Exonuclease I and FastAP™ Thermosensi-
tive Alkaline Phosphatase (Fermentas Life Science) [24].
Sanger sequencing was done by Inqaba Biotechnological
Industries using the ABI Big Dye Terminator Cycle Se-
quencing kit version 3.1 and 3130 XL and 3500XL se-
quencer systems (Applied Biosystems Inc.) and primers
described in Additional file 4: Table S4.
Electropherograms were edited using FinchTV version
1.4.0 (Copyright © 2004–2006, Geospiza Inc.). Following
editing, sequences were imported into CLC DNA
Workbench version 5.5 (CLCBio, Aarhus, Denmark),
assembled and compared to the CYP2D6 reference se-
quence AY545216 (GenBank). As with the AmpliChip,
CYP2D6 sequence variations were numbered and alleles
were assigned according the P450 Nomenclature Com-
mittee website.Evaluation of exon 9 gene conversion
The presence of non-functional CYP2D6*4 N and *36
allelic variants where evaluated by assaying for the
presence of a CYP2D7 gene conversion in exon 9.
The PCR reaction (primers and conditions in Additional
file 3 Table S3) was performed as described by Gaedigk
et al. [25] using BIOTAQ™ DNA Polymerase (Bioline,
London, UK). The amplicon was analysed using 3%
agarose gel electrophoresis.Characterisation of novel alleles
To characterise haplotypes associated with novel non-
synonymous SNPs, a 6.6 kb long PCR product was ampli-
fied using CYP2D6 specific primers described previously
[23]. This product was cloned using the CloneJET ™ PCR
Cloning Kit (Fermentas Life Science) according to manu-
facturer’s instructions and transformed into DH5α cells
(Zymo Research, Orange, CA, USA). Colonies were
screened by amplifying the region of interest (where the
novel SNP was located) using relevant sequencing primers
followed by sequencing. Once the correct colony was
identified, colony extraction was performed using Zuppy™
Plasmid Miniprep Kit (Zymo Research) and sequenced as
described above. The haplotype of the novel allele was
determined by comparing the sequence obtained from the
cloned allele and the sequence of the XL-PCR product
representing both alleles. Novel allele defining non-
synonymous SNPs were analysed using “sorting intolerant
from tolerant” (SIFT) and PolyPhen prediction software
which estimates the effect on CYP2D6 activity in silico
[26,27]. Potential splice site variation was evaluated in
silico using NetGene2 [28,29]. Novel allele sequences were
submitted to the CYP Allele Nomenclature Committee for
CYP2D6 allele designation.Phenotype prediction
AmpliChip software predicted phenotype based on prin-
ciples explained in Table 2 (AmpliChip CYP450 Test
package insert). The Activity Score (AS) model [30] was
used to predict phenotype from data generated by
CYP2D6 re-sequencing and the AmpliChip. AS was cal-
culated using model A [30]. Novel alleles were assigned
an AS of 1.0 to allow for phenotypic comparison, since
actual enzyme activity has not yet been confirmed. The
exception was CYP2D6*4P; its novel non-synonymous
SNP was linked with 1846 G>A, the CYP2D6*4-defining
SNP that causes a splice defect thereby obliterating ac-
tivity (AS=0). The AS was also adopted to predict
CYP2C19 phenotype, which is explained in Table 2.
Statistics
Tools for Population Genetic Analysis (TFPGA) software
v1.3 (Miller, 1997: http://www.marksgeneticsoftware.net/
tfpga.htm) was used (i) to test allele deviation from a
Hardy-Weinberg equilibrium using a Fisher’s exact test
for each ethnic group within each cohort and (ii) for
comparing platforms using Fisher’s exact test. Linkage
disequilibrium was evaluated using Haploview software
v3.31 [31]. A P value of <0.05 was considered to be
significant.
Results
Success rate of the AmpliChip CYP450 Test
Cohort 1 (n=83) had a success rate with AmpliChip of
75.9% for CYP2D6 and 98.8% for CYP2C19. There were
five “No Calls” (all hybridisation positions were occupied
and identified by the AmpliChip software, but based on
the hybridisation pattern a genotype could not be gener-
ated, nor a phenotype predicted) for CYP2D6, raising
the success rate of the AmpliChip to 81.9% with only
75.9% generating pharmacogenetically relevant data.
None of the failed AmpliChips were repeated for this
group.
Cohort 2 (n=100) had a success rate of 71.0% for
CYP2D6. Of the AmpliChip micorarrays which failed to
generate a genotype, 4.0% were “No Calls”. Therefore,
75.0% of the microarrays were successful, of which only
71.0% gave pharmacogenetically relevant results. The
most frequent hybridisation failures in both cohorts
were at the 1758 G locus, which is associated with
CYP2D6*8 (1758 G>T) and *14 (1758 G>A) alleles. The
AmpliChip information leaflet mentioned that this
would indeed be the most likely hybridisation locus to
fail. For CYP2C19, 100.0% of the AmpliChips generated
a genotype, and a predicted phenotype could thus be
assigned in all cases.
Thirteen failed samples and two successful samples
(positive controls) were repeated in order to estimate
user error. The two samples which had succeeded
Table 2 CYP2D6 and CYP2C19 phenotype prediction
Estimated metabolic potential of alleles
CYP2D6 Allele activity Numeric activity CYP2C19
*1xN, *2xN Increased 2.0 *17
*1,*2, *22, *33, *35, *43, *45B, *46 Normal 1.0 *1+, *28
*10, *17, *29, *41, *59 Decreased 0.5 *9, *27
*4, *5, *14, *16, *40, *56B, *4xN Absent 0.0 *2, *3
*25, *30, *64, *65, *73, *74, *84, *85, *86 Unknown 1.0 *15
(Activity according to http://www.cypalleles.ki.se/)
Phenotype prediction
AmpliChip Prediction Activity Score (AS)
3 or more functional alleles UM > 2.0
1 or 2 functional alleles and increased paired with decreased or absent EM 1.5-2.0
1 or 2 reduced function alleles IM 0.5-1.0
2 absent function alleles PM 0.0
Alleles for both genes present in this table are relevant to this study; additional allele information is available at http://www.cypalleles.ki.se/. The activity of each
allele in the genotype is used to predict phenotype. CYP2D6 Activity Score (AS) is assigned according to model A proposed by Gaedigk et al. (2008). The AS was
adopted to predict CYP2C19 activity.
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ures, two succeeded, three failed (but hybridised at
additional loci), one failed at different loci and the
balance failed as they did before (missing the same
hybridisation loci).CYP2C19 genotype analysis
AmpliChip
Using AmpliChip to evaluate genotype, it was found
that there were no statistically significant differences in
CYP2C19 allele frequencies between the two sampled
cohorts (P>0.08) and all alleles were in Hardy-Weinberg
equilibrium in both cohorts (Table 3). Typically rare,
CYP2C19*3 only occurred in Cohort 1, but was relatively
infrequent and not statistically significant.PCR-RFLP
The PCR-RFLP platform identified high frequencies
(refer to Table 3; P≤0.002) of CYP2C19*15 (unknown),
*17 (increased metabolism) and *27 (decreased metabol-
ism). Although not significant (P=0.058) when combin-
ing ethnicities, CYP2C19*9 (decreased metabolism) was
present at high frequency (P=0.029) over the whole
cohort, when only Black Africans were compared
between platforms. Interestingly, four samples (three
Black Africans and one Indian) were homozygous for
CYP2C19*2, but were also heterozygous for the *27
allele. This suggests that the 19154 G>A and -1401 G>A
SNPs used for CYP2C19*2 and *27 detection respect-
ively, may be in partial LD with one another, forming
an additional allele. The combination was listed as
CYP2C19*2, since the presence of the 19154 G>Asplicing defect would be the allele-defining SNP as it
causes a non-functional gene product.
Predicted Phenotype
The only difference between the two cohorts for
AmpliChip predicted phenotype was PM for White
Caucasians, as there were more identified in cohort 1.
Caution should be taken when making this compari-
son, as this 16.7% frequency is only one individual
in the cohort and the sample size is not statistically
large enough to make a valid comparison. The adop-
tion of AS combined with CYP2C19 PCR-RFLP
allows IMs to be assigned and also changes the iden-
tification profile of PMs (refer to Table 3). EM and
PM predicted phenotype in Black Africans following
CYP2C19 PCR-RFLP correlated well with the Xhosa
individuals screened by Drögemöller et al. [18], but
IM and UM seem to be different.
CYP2D6 genotype analysis
AmpliChip
Table 4 summarises the CYP2D6 allele frequencies for
the sampled cohorts and compares allele frequencies be-
tween cohorts and platforms [14,17,34]. The only allele
which was out of Hardy-Weinberg equilibrium was
CYP2C19*10 (P=0.006) in cohort 1. CYP2D6*17 was the
only allele with significant allele frequency differences
(P=0.045) between the two cohorts which is likely to
be the result of a larger number of Black Africans in
cohort 2. AmpliChip found Black African individuals in
both cohorts to have a relatively high frequency of
CYP2D6*17 and CYP2D6*41. CYP2D6 *4 and *41
were relatively frequent in the Caucasian, Coloured and
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source for potential PM (refer to Table 4).XL-PCR+Sequencing
CYP2D6 re-sequencing not only contributed to a
comprehensive assessment of known CYP2D6 se-
quence variations, but also allowed identification of
novel allelic variants. A total of 92 sequence varia-
tions were identified including 88 SNPs, two inser-
tions and two deletions (Additional file 5: Table S5).
Additional novel SNPs were identified, but were not
assigned to alleles as no apparent clinical relevance
was observed (Additional file 5: Table S5). None of
these SNPs were found to impact splicing based on
the NetGene2 prediction.
Twenty one distinct alleles were identified in Cohort 2
(Additional file 6: Figure S1). Of the clinically relevant
alleles identified by this platform, CYP2D6*17 and *5
were frequently observed in the Black population. In
contrast CYP2D6*4 and *41 alleles were frequent in
Caucasians and CYP2D6*4 in the Coloured population
groups. Of the alleles identified by gene re-sequencing
(n=200 successful identifications), 17.0% (n=34) had ab-
sent, 31.5% (n=63) decreased, 51.% (n=102) normal and
0.5% (n=1) increased enzyme function in the sampledTable 3 CYP2C19 allele and predicted phenotype frequency in
cohort (n=100) compared to other cohorts sampled in SA










*1+ Normal 85.7 75.0 75.0 60.0 1.000 82
*2 Absent 116 25.0 25.0 40.0 0.784 17
*3 Absent 2.7 0.0 0.0 0.0 0.084 0.
*9 Decreased − − − − − −
*15 Unknown − − − − − −
*17 Increaased − − − − − −
*27 Decreased − − − − −




112.0 12.0 20.0 20.0 140
Predicted Phenotyp
PM 3.5 16.7 10.0 30.0 7.
IM 0.0 0.0 0.0 0.0 0.
EM 94.7 83.3 90.0 70.0 92
UM 0.0 0.0 0.0 0.0 0.
Failure 1.8 0.0 0.0 0.0 0.
Cohort (n) 57 6 10 10 70cohort. All alleles described by sequencing were in
Hardy-Weinberg Equilibrium.Allele comparison between platforms
The most noticeable discrepancy between the two plat-
forms was that AmpliChip identified fewer CYP2D6*2
alleles (not significant; P=0.107) and more *41 alleles
(P<0.001). The normal function CYP2D6*45B (n=8) and
*46 (n=1) alleles was not identified by AmpliChip and
was incorrectly assigned as reduced function *41. Simi-
larly, AmpliChip identified the non-functional CYP2D-
6*56B (n=1) as a reduced function CYP2D6*10B allele.
Of the 200 alleles tested, AmpliChip identified nine
CYP2D6*5 alleles compared to the seventeen identified
by the Hersberger et al. [22] assay, of which only five
subjects were accurately identified by both assays. This
difference was significant (P=0.037). When investigated
further, the Hersberger et al. [22] assay predicted nine
individuals to be heterozygous CYP2D6*5 while Ampli-
Chip reported homozygous *1 (n=1), *2 (n=1), *4 (n=1),
*17 (n=5) or *41 (n=1) genotypes. Eighteen alleles identi-
fied by the XL-PCR+Sequencing platform were not
identified by AmpliChip. In addition to CYP2D6*45B,
*46 and *56B mentioned above, CYP2D6*59 (reduced
function) was misidentified as CYP2D6*2 or *22 (botha demographically representative South African (SA)












.1 95.0 65.0 65.0 0.000 32.1 70.0
.9 5.0 35.0 35.0 1.000 17.9 5.0
0 0.0 0.0 0.0 1.000 0.0 0.0
− − − 0.058 3.6 0.0
− − − 0.002 5.7 0.0
− − − 0.000 16.4 25.0
− −− − 0.000 24.3 0.0
− − − 1.000 0.0 0.0
.0 20.0 20.0 20.0 140.0 20.0
e Frequency (%)
1 0.0 10.0 10.0 5.7 0.0
0 0.0 0.0 0.0 21.4 10.0
.9 100.0 90.0 90.0 45.7 90.0
0 0.0 0.0 0.0 27.1 0.0
0 0.0 0.0 0.0 0.0 0.0
10 10 10 70 10
















*1+ Normal 40.0 40.0 78.0 23.0 17.0 41.0 63.0 71.0 77.0
*2 Absent 35.0 35.0 22.0 61.0 21.0 17.0 22.0 20.0 17.0
*3 Absent 0.0 0.0 0.0 16.0 0.0 7.0 − − 0.0
*9 Decreased 0.0 0.0 − − 9.0 4.0 − − 6.0
*15 Unknown 10.0 0.0 − − 9.0 8.0 − − 0.0
*17 Increaased 0.0 5.0 − − 10.0 14.0 15.0 9.0 −
*27 Decreased 15.0 20.0 − − 33.0 8.0 − − −




20.0 20.0 152.0 1964-1970 200.0 150.0 218.0 134.0 18.0
Predicted Phenotype Frequency (%)
PM 20.0 50.0 5.3 1.5 3.0 8.0 − − −
IM 50.0 40.0 32.9 13.0 49.0 40.0 − − −
EM 30.0 0.0 61.6 85.5 39.0 35.0 − − −
UM 0.0 10.0 0.0 0.0 9.0 17.0 − − −
Failure 0.0 0.0 0.0 1.1-0.8 0.0 0.0 0.0 0.0 0.0
Cohort (n) 10 10 76 982-985 100 75 109 67 9
Allele frequencies for each allele were compared between cohorts and platforms. Allele frequencies for different ethnicities were summed for comparison. Genetic
material for cohort 2 was genotyped using PCR-RFLP to evaluate AmpliChip CYP450 TestW (AmpliChip) genotype calls. CYP2C19*1+ : wild type and any
unidentified alleles; —:alleles not identified by assay or predicted phenotype not reported.
Table 3 CYP2C19 allele and predicted phenotype frequency in a demographically representative South African (SA)
cohort (n=100) compared to other cohorts sampled in SA (Continued)
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http://www.biomedcentral.com/1471-2350/14/20normal function). CYP2D6*33 and*43 (both normal
function) were identified as CYP2D6*1 (normal
function).
Predicted phenotype
There were more PMs identified in Cohort 1 than in
Cohort 2. The XL-PCR+Sequencing platform did not
identify more PMs in Cohort 2, but increased prediction
of IMs. XL-PCR+Sequencing compared well with the
cohort described by Wright et al. [17]; there were how-
ever, fewer PMs.
CYP2D6 novel alleles
Figure 1 displays the four novel alleles we identified by
XL-PCR+Sequencing in comparison to other similar
alleles. The CYP2D6*4P allele was found in a Caucasian
individual. Due to the detrimental 1846 G>A SNP that
causes aberrant splicing, CYP2D6*4P the novel 4157 T>G
SNP did not require further characterisation. This allele
received an AS of 0.0 classifying it as non-functional.
CYP2D6*84 has a *2A backbone and was found in
a Black African individual. The allele-defining SNP
2574C>A in exon 5 that results in an amino acid change
(P267H) was predicted to be benign by PolyPhen (PSICscore of 0.871), but SIFT predicted it to affect protein
function (SIFT score of 0.03). The amino acid change
was from a non-polar proline to a basic histidine, which
results in a charge change, thereby supporting the possi-
bility of altered activity. As there is a discrepancy be-
tween the in silico prediction tools, an AS score of 1.0
was given to this allele for comparative purposes.
CYP2D6*85 was also found in a Black African indivi-
dual. The allele defining SNP for CYP2D6*85 was
4157 T>G that results in a H478Q amino acid change.
According to PolyPhen (PSIC=0.419) and SIFT (SIFT=
0.58) this change is unlikely to affect activity. Therefore,
we assigned an AS of 1.0 to this allele. CYP2D6*85 also
has a CYP2D6*2 backbone.
The final novel allele, CYP2D6*86, was discovered in
an Indian individual. Only two SNPs 2606 G>A and
2610 T>A were observed, and both caused an amino
acid change, i.e. E278K and M279K. However, only
2610 T>A was predicted to be likely to affect protein
function by PolyPhen, (PSIC=1.905, SIFT=0.01) due to a
hydrophobicity change from a non-polar to a basic
amino acid in a buried site. The other SNP, 2606 G>A,
is unlikely to affect enzyme activity (PSIC=0.205,
SIFT=0.07). However, because the 2610 T>A was not
Table 4 CYP2D6 allele and predicted phenotype frequency in a demographically representative South African (SA)
cohort (n=100) compared to other cohorts sampled in SA
Cohort 1 AmpliChip Comparison Cohort 2 AmpliChip
Allele Activity Black African White Caucasian Coloured Indian Fischer's Exact Black African White Caucasian Coloured Indian
Allele Frequency (%)
*1 Normal 30.7 40.0 38.9 30.0 0.301 20.0 31.0 37.5 60.0
*2 Normal 4.5 20.0 0.0 30.0 1.000 20. 18.8 18.8 30.0
*4 Absent 2.3 10.0 16.7 10.0 0.795 0.0 31.3 12.5 0.0
*5 Absent 5.7 10.0 0.0 0.0 0.523 4.0 0.0 0.0 0.0
*10 Decreased 6.8 0.0 0.0 10.0 1.000 6.0 6.3 6.3 0.0
*14 Absent 0.0 0.0 0.0 0.0 1.000 0.0 0.0 0.0 0.0
*16 Absent − − − − − − − − −
*17 Decreased 13.6 0.0 11.1 0.0 0.045 31.0 0.0 0.0 0.0
*22 Normal − − − − − − − − −
*25 Unknown 0.0 0.0 0.0 0.0 1.000 1.0 0.0 0.0 0.0
*29 Decreased 13.6 0.0 0.0 0.0 1.000 6.0 0.0 6.3 0.0
*30 Unknown 1.1 0.0 0.0 0.0 0.461 0.0 0.0 0.0 0.0
*33 Normal − − − − − − − − −
*35 Normal 0.0 0.0 0.0 0.0 1.000 0.0 0.0 6.3 0.0
*36 Reduced 0.0 0.0 0.0 0.0 1.000 0.0 0.0 0.0 0.0
*40 Absent 1.1 10.0 5.6 0.0 1.000 3.0 0.0 0.0 0.0
*41 Decreased 20.5 10.0 27.8 20.0 0.883 26.0 12.5 12.5 10.0
*43 Normal − − − − − − − − −
*45B Normal − − − − − − − − −
*46 Normal − − − − − − − − −
*56B Absent − − − − − − − − −
*59 Decreased − − − − − − − − −
*64 Unknown − − − − − − − − −
*65 Unknown − − − − − − − − −
*73 Unknown − − − − − − − − −
*74 Unknown − − − − − − − − −
*84 Normal − − − − − − − − −
*85 Normal − − − − − − − − −
*86 Normal − − − − − − − − −
*1xN Increased 0.0 0.0 0.0 0.0 1.000 0.0 0.0 0.0 0.0
*2xN Increased 0.0 0.0 0.0 0.0 1.000 1.0 0.0 0.0 0.0
*4xN Absent 0.0 0.0 0.0 0.0 1.000 0.0 0.0 0.0 0.0
Hybrid alleles − − − − − − − − −
Alleles identified (n) 88 10 18 10 100 16 16 10
Predicted Phenotype Frequency (%)
PM 3.5 83.3 10.0 0.0 0.0 10.0 0.0 0.0
IM 28.1 0.0 20.0 0.0 42.9 10.0 20.0 0.0
EM 43.9 0.0 60.0 50.0 27.1 60.0 60.0 50.0
UM 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Unknown 1.8 0.0 0.0 0.0 1.4 0.0 0.0 0.0
No call 7.0 0.0 0.0 0.0 5.7 0.0 0.0 0.0
Failure 15.8 16.7 10.0 40.0 22.9 20.0 20.0 50.0
Cohort (n) 57 6 10 10 70 10 10 10
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Comparison XL-PCR + Sequencing Dandaraet al. 2001
Gaedigk












*1 0.715 25.7 30.0 30.0 45.0 50.0 26.8 23.6 24.5
*2 0.107 8.6 15.0 15.0 30.0 17.8 15.2 12.3 15.7
*4 0.586 0.0 20.0 15.0 0.0 3.3 7.1 1.9 1.0
*5 0.037 10.7 5.0 5.0 0.0 4.6 17.2 14.2 18.6
*10 0.808 5.7 5.0 5.0 0.0 − 2.5 1.9 2.0
*14 1.000 0.0 0.0 0.0 0.0 − 0.5 0.0 0.0
*16 1.000 0.0 0.0 0.0 0.0 − 0.5 0.0 0.0
*17 0.584 25.7 0.0 10.0 0.0 24.0 12.6 13.2 16.7
*22 1.000 0.0 0.0 0.0 5.0 − — — —
*25 0.416 0.0 0.0 0.0 0.0 − — — —
*29 0.598 4.3 0.0 5.0 0.0 − 4.6 13.2 6.9
*30 1.000 0.0 0.0 0.0 0.0 − — 0.0 0.0
*33 1.000 0.0 5.0 0.0 0.0 − — — —
*35 1.000 0.0 5.0 0.0 0.0 − — — —
*36 1.000 0.0 0.0 0.0 0.0 − 0.0 0.0 0.0
*40 1.000 3.6 0.0 0.0 0.0 − 0.0 1.9 2.9
*41 0.000 0.7 15.0 5.0 10. − 0.0 1.9 1.0
*43 0.272 0.7 0.0 5.0 5.0 − — 0.9 1.0
*45B 0.020 5.7 0.0 0.0 0.0 − 0.0 10.4 1.0
*46 1.000 0.7 0.0 0.0 0.0 − 0.0 0.0 0.0
*56B 1.000 0.7 0.0 0.0 0.0 − 0.0 — —
*59 1.000 0.0 0.0 0.5 0.0 − — — —
*64 1.000 0.0 0.0 0.0 0.0 − 0.0 0.0 0.0
*65 1.000 0.0 0.0 0.0 0.0 − 0.0 0.0 0.0
*73 1.000 0.0 0.0 0.0 0.0 − — 0.0 1.0
*74 1.000 0.0 0.0 0.0 0.0 − — 0.0 1.0
*84 1.000 0.7 0.0 0.0 0.0 − — — —
*85 1.000 0.7 0.0 0.0 0.0 − — — —
*86 1.000 0.0 0.0 0.0 5.0 − — — —
*1xN 1.000 0.0 0.0 0.0 0.0 − 0.0 0.0 1.0
*2xN 1.000 0.7 0.0 0.0 0.0 − 0.0 2.8 2.9
*4xN 0.147 2.9 0.0 0.0 0.0 − 0.0 1.9 2.9
Hybrid alleles − − − − − − 0.0 0.0 0.0
Alleles identified (n) 140 20 20 20 152 198 106 102
Predicted Phenotype Frequency (%)
PM 0.0 10.0 0.0 0.0 2.6 3.0 3.8 7.8
IM 42.9 30.0 50.0 0.0 56.6 53.0 47.2 37.3
EM 57.1 60.0 50.0 100.0 40.8 39.0 43.4 47.1
UM 0.0 0.0 0.0 0.0 0.0 4.0 5.7 7.8
Unknown 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Table 4 CYP2D6 allele and predicted phenotype frequency in a demographically representative South African (SA)
cohort (n=100) compared to other cohorts sampled in SA (Continued)
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No call 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Failure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Cohort (n) 70 10 10 10 76 99 53 51
Allele frequencies for each allele were compared between cohorts and platforms for statistical comparison. Allele frequencies for different ethnicities were
summed for comparison. Genetic material for cohort 2 was sequenced to evaluate AmpliChip CYP450 TestW (AmpliChip) genotype calls. Lower allele numbers
were reported for the AmpliChip due to “No Calls” and failed chips. Individuals could be predicted as poor (PM), intermediate (IM), extensive (EM) and ultrarapid
metabolisers using AmpliChip or activity score prediction models. xN: multiple copies of the allele detected; —, alleles not identified by platform.
Table 4 CYP2D6 allele and predicted phenotype frequency in a demographically representative South African (SA)
cohort (n=100) compared to other cohorts sampled in SA (Continued)
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http://www.biomedcentral.com/1471-2350/14/20confirmed to alter activity, the CYP2D6*86 allele was
assigned an AS score of 1.0 for comparative purposes.
Both SNPs have been described previously, but not
within a defined allele (Tandon et al. manuscript in
preparation, http://www.cypalleles.ki.se/cyp2d6.htm).
Discussion
The ability of AmpliChip to simultaneously assay for
CYP2D6 gene duplications, gene deletions as well as
33 CYP2D6 and 3 CYP2C19 variants simultaneously,
characterises it as high-throughput. However, several
limitations were identified which question the use of
AmpliChip in the South African population.
First, AmpliChip performed poorly in terms of reliabil-
ity. For CYP2D6 the average failure rate in both groups
was 22.4%. In addition, only 2 out of the 13 samples that
failed on first attempt succeeded after a second attempt,
raising the concern of cost effectiveness. Possible expla-
nations for the poor success rate of AmpliChip in this
population include (i) suboptimal transportation condi-
tions and mishandling during transfer possibly damaging
the microarrays; (ii) concerns regarding the length of the
amplification - this has previously been suggested to be
a weak point in the assay [7]. Rebsamen et al. [9] sup-
ported this proposal and identified gene duplication
errors. However, each amplification reaction was tested
for product using 1.0% agarose gel electrophoresis prior
to proceeding to the fragmentation step. The failures
observed are therefore unlikely to be due to the lack of a
PCR product; (iii) inadequate fragmentation, which in
turn impacts on hybridisation, thereby rendering the test
a failure. In 2007, the FDA reported that the DNase I
recommended in the AmpliChip information leaflet was
of reduced quality, resulting in low specific activity
(http://www.fda.gov/Safety/Recalls/EnforcementReports/
2007/ucm120450.htm); (iv) lack of standardisation of
the strepravidin R-phycoerythrin conjugate. Roche has
stopped supplying the recommended reagent and has
not recommended a suitable replacement.
The high frequency of unknown predicted phenotypes
called by AmpliChip is a serious limitation for routine
implementation in the South African population. Ap-
proximately 7.7% predicted phenotypes were “Unknown”
even though AmpliChip was successful. These indi-
viduals would not have benefited from pharmacogeneticscreening by AmpliChip for CYP2D6. This questions the
use of this pharmacogenetic screening assay in the South
African population as the frequency of the “Unknown”
predicted phenotype is higher than the frequency of
PMs identified (1.0-9.6%). With AmpliChip being more
expensive that the other platforms and having a low suc-
cess rate, AmpliChip will not assist in reducing the fi-
nancial burden associated with CYP2C19 and CYP2D6
associated ADRs.
AmpliChip compared to CYP2C19 PCR-RFLP platform
The ability to cover population-specific alleles is another
limitation. AmpliChip may have had a high success rate
for CYP2C19, and the frequencies compared well with
previously reported values in various African popula-
tions [7,35], but there may be several mutations which
AmpliChip was unable to identify (i.e. CYP2C19 alleles
*2 and *3 were discovered). Thus, there may be a higher
frequency of alternative polymorphisms resulting in ab-
sent (CYP2C19*4, *5, *6, *7 and *8) or increased (*17)
enzyme function (http://www.cypalleles.ki.se/). Addition-
ally, a glimpse into the South African Xhosa and Cape
Mixed Ancestry (Coloured) populations has revealed a
novel mutation in the promoter region -1041 G>A
(CYP2C19*27) which was found to be present at a rela-
tively high frequency of 33.0% [18]. In silico analyses and
luciferase expression assays suggest that this polymorph-
ism may result in reduced expression of CYP2C19 [18].
The absence of these important alleles from AmpliChip
highlights the need to develop a more specific and/or
comprehensive assay for this population.
The more comprehensive PCR-RFLP genotyping me-
thod identified 83 alleles out of 158 that were wrongly
assigned by AmpliChip as “CYP2C19*1” (i.e. wild type
and unidentified alleles). This is significant for the accur-
acy of downstream phenotype prediction and agrees
with concerns that the CYP2C19 alleles identified by
AmpliChip, would not be comprehensive enough for the
South African population. The incorrect assignment of
“CYP2C19*1” was especially relevant to the Black South
African cohort, as 48.6% of the alleles initially assigned
as “CYP2C19*1” by AmpliChip, were assigned other
alleles after PCR-RFLP genotyping (Table 3). However,
the effect of these alleles needs to be carefully consid-
ered before drawing firm conclusions.
Figure 1 Schematic diagram representing novel CYP2D6*4P, *84, *85 and *86 alleles identified in the South African cohort described in
this study. Polymorphisms are represented by black blocks. Allele defining polymorphism are indicated by a white star. These alleles have been
accepted by the CYP Allele Nomenclature Committee for CYP2D6 (http://www.imm.ki.se/CYPalleles/). CYP2D6*2A and *4 used for comparison,
were adopted from Gaedigk et al. [23]. BL: Black African; CA: Caucasian; IN: Indian; UTR: untranslated region; Ex: exon; In: intron.
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http://www.biomedcentral.com/1471-2350/14/20The variation in the LD pattern observed for the
CYP2C19*2 and *27 defining SNPs, identified in the
three Black Africans and one Indian individual, but was
not observed in the small Caucasian cohort. This alter-
native LD was identified previously in a Black African
population [18] and one should be aware of the clinical
implications of this. For example, if CYP2C19*27 was re-
sponsible for decreased metabolism, an individual testing
positive for both the *2 and *27 alleles could be *2/*27
(AS=0.5) or *2+*27/*1 (AS=1). The low LD observed
predominantly in Africans may complicate the assign-
ment of alleles and may necessitate the genotyping of
multiple SNPs before allele assignment.
Considering the high frequencies observed for CYP-
2C19*17 in a variety of populations [36-40] and the
identification of other high frequency alleles such as *27
[18], which may have clinical implications, it could be
argued that AmpliChip is not comprehensive enough for
any population. In addition, AmpliChip is a relatively ex-
pensive assay for prediction of CYP2C19 phenotype and
a population specific, reasonably priced assay such as
PCR-RFLP is advised for future phenotype prediction,
especially in developing countries where resources are
limited.
AmpliChip compared to the CYP2D6 XL-PCR+Sequencing
platform
As our cohort represented a diverse population it was
not surprising to find a large number of CYP2D6 allelicvariants as well as four novel alleles. Nine CYP2D6*2
alleles were miss-called as *41, resulting in an over
estimation of CYP2D6*41/*41 homozygotes [41]. The
AmpliChip-derived frequency of CYP2D6*41 among our
Black subjects was therefore higher when compared to
similar cohorts [35], in which the CYP2D6*41 allele was
detected by its key SNP (2988 G>A). AmpliChip designates
CYP2D6*41 using the -1584 C>G variation and linkage dis-
equilibrium with other SNPs, which generally hold true in
Caucasians, but not in subjects of Black African ancestry
[41]. Furthermore, using the CYP2D6*41 key SNP will also
allow differentiation of CYP2D6*41 from *45B and *46
alleles which are not identified by AmpliChip.
CYP2D6*1 was incorrectly assigned as *41 by Ampli-
Chip five times. This could possibly be due to the lack of
hybridisation. These inaccurate genotype assignments
affect the prediction of subjects’ phenotypes to various
extents. In addition, AmpliChip does not contain identi-
fying, or key SNPs for CYP2D6*45, *46, *56 and *59,
which we have discovered by the XL-PCR+Sequencing
platform and hence, defaulted these alleles to CYP2D6*2
or *10 according to the AmpliChip algorithm. Inaccurate
results in combination with alleles that are not captured
by AmpliChip could have serious pharmacogenetic and
clinical implications.
Predicted phenotype
There was a noticeable difference in phenotypic predic-
tion between AmpliChip and the AS for both CYP2D6
Dodgen et al. BMC Medical Genetics 2013, 14:20 Page 13 of 15
http://www.biomedcentral.com/1471-2350/14/20and CYP2C19. This was apparent when comparing each
system on both a group to group and combined level.
Accurate phenotype prediction appears to be a limitation
of AmpliChip which supports the use of a numeric
method for phenotype identification [7,9,30]. In addition,
a 93% CYP2C19 EM prediction may be an overestimate.
Use of the numeric AS allows for CYP2C19 IM to be
predicted; this is a subset of the cohort that could poten-
tially benefit from pharmacogenetic screening. Articles
comparing clopidogrel (prodrug) response to CYP2C19
variability have demonstrated reduced metabolism in
individuals who have CYP2C19*1/*2 or *1/*3 allele
combinations. These genotypes were associated with
normal or only slightly reduced platelet aggregation, as
clopidogrel needs to be metabolised into its active me-
tabolite in order to affect platelet aggregation [42-44]. It
may therefore be more appropriate to split this EM
group into EM and IM. In this way *1/*2 and *1/*3 indi-
viduals could potentially benefit from pharmacogenetic
screening. Measured phenotype would be needed to fully
understand and evaluate phenotype prediction by the
various platforms. With the AmpliChip not identifying
the increased function CYP2C19*17, tailoring of clopido-
grel dosage would be difficult.
Pharmacogenetic relevance for the South African
population
The possible existence of additional functionally relevant
alleles unique to the South African population will need
to be considered if CYP2D6 and CYP2C19 pharmaco-
genetics are to be applied in this population [45]. With
the large amount of genetic variation observed in this
South African cohort it would be essential to use more
comprehensive platforms for pharmacogenetic screening
to ensure a more accurate predicted phenotype. Pre-
dicted phenotype may not be clinically relevant if geno-
typing is incomplete and inaccurate, highlighting
the importance of establishing novel approaches for
predicting phenotype [7,30]. It will also be important to
compare genotype and measured phenotype in this
population, to assess the accuracy of the predicted
phenotype called by AmpliChip [14] as well as other
prediction strategies. Due to the high failure rate and
high cost of AmpliChip it is not feasible to repeat these
AmpliChips to evaluate the cause for error.
Conclusion
When applied to a demographically-representative sam-
ple of the South African population, the AmpliChip had
a low success rate and a high number of unknown pre-
dicted phenotype calls were observed. This platform
would need to be refined before being applied as a pre-
prescription pharmacogenetic screening tool in this, and
possibly other genetically-diverse African populations.Alternative platforms for genotyping, such as the ones
used in this study, would be more clinically appro-
priate for pharmacogenetic screening of CYP2D6 and
CYP2C19. With the rapid advance in sequencing tech-
nologies, read lengths are improving which will allow
sequencing to form the basis of pharmacogenetics in the
future. This will facilitate simultaneous identification of
novel alleles in complex populations. The comparison
between predicted phenotype and measured phenotype
will also need to be considered.
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